FDA New Drug Application In The Works For This Innovator In ADHD Drug Delivery

Shane Schaffer, Chairman & CEO, and Peter J. Werth, Board Member of Cingulate CING, were recently guests on Benzinga's All Access.

Cingulate is a biotechnology company that is developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, allowing for relief of the pill burden many people with chronic conditions suffer.

The company is preparing an application for new drug approval for its lead candidate, CTx-1301.

Watch the full interview here:

Featured photo by danilo.alvesd on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.